New clinical trial finds Gencor’s Levagen+ improves body power and strength
28 Jun 2024 --- The second clinical trial on Gencor’s highly bioavailable form of palmitoylethanolamide (PEA) ingredient, Levagen+, for the active nutrition category, observed that it significantly improves lower body power and does not interfere with skeletal muscle hypertrophy gains.
“To our knowledge, this is the first study to investigate the effects of PEA on the adaptive responses to strength training. This is our second study investigating Levagen+ for active nutrition, and it continues to show great promise in this category,” says Ramasamy Venkatesh, co-founder and managing director of Gencor.
Queries about strength training
The randomized, double-blinded, placebo-controlled clinical study was published in the high-impact factor journal Sports Medicine.
The study aimed to evaluate the effects of daily Levagen+ supplementation combined with eight weeks of resistance training in healthy, active male and female participants. PEA has demonstrated significant potential as a viable alternative to over-the-counter medications’ adverse skeletal muscle effects for its analgesic and healthy inflammatory response properties.
The findings show that a daily dose of 350 mg of Levagen+ improves lower body power and isometric strength by 17% compared to the placebo group by 5%. PEA supplementation did not inhibit strength training adaptations like non-steroidal anti-inflammatory drugs and other analgesics.
Bioavailable form of PEA
Levagen+ is a highly bioavailable form of PEA created using a state-of-the-art delivery technology called LipiSperse, developed by Pharmako Biotechnologies.
It is manufactured in Current Good Manufacturing Practice facilities and has been clinically shown to support joint health, sleep, recovery, immunity, aches and discomforts and a healthy inflammation response.
Levagen+ applies to dietary supplements, F&B and cosmeceuticals.
Meanwhile, another trial revealed that Levagen+ can help alleviate the discomfort associated with migraine headaches. The study also found that it reduces the duration of migraines in healthy individuals.
In addition, Levagen+ was found to reduce pain in people suffering from diabetic peripheral neuropathy, posing a potential healthy aging solution.
To contact our editorial team please email us at editorial@cnsmedia.com
Subscribe now to receive the latest news directly into your inbox.
COMPANY DETAILS
999 Gaoxin Ave, Wuhan East Lake High-tech Development Zone
Wuhan
430073
China
www.cabio.com
info@cabio.cn
Tel: 86 (27) 67845351HEALTH CATEGORIES
